Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials

Background: Pooled analysis of phase 3, double-blind, doubledummy ECHO and THRIVE trials comparing rilpivirine (TMC278) and efavirenz. Methods: Treatment-naive HIV-1-infected adults were randomized 1:1 to rilpivirine 25 mg once daily or efavirenz 600 mg once daily, with background tenofovir disoprox...

Full description

Saved in:
Bibliographic Details
Main Authors: Cohen C., Molina J., Cahn P., Clotet B., Fourie J., Grinsztejn B., Wu H., Johnson M., Saag M., Supparatpinyo K., Crauwels H., Lefebvre E., Rimsky L., Vanveggel S., Williams P., Boven K.
Format: Journal
Published: 2017
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84862777419&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/42848
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University